AMX0035 was tested at UF, Mass General and partnering sites and then approved by the FDA to treat ALS.
Ariel Walker is the latest MBI Rising Star, a video series highlighting up-and-coming neuroscience researchers at UF.
Trial drug combination shows potential to prolong survival of ALS patients by more than six months.
UF was the No. 2 enroller of patients for multisite ALS trial.
Novel type of immunotherapy used in mouse-model study shows promise for ALS treatment.